Talk:Rituximab

From Wikipedia, the free encyclopedia

	This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
Start	This page has been rated as Start-Class on the quality assessment scale
High	This article has been rated as High-importance on the importance assessment scale

Contents 1 Use of rituximab 2 SLE 3 Epitope on CD20 4 NHS approval

[edit] Use of rituximab

While it is true that the FDA-approved use of rituximab is for relapsed or refractory lymphoma, its off label use in combination with CHOP is standard clinical practice in the U.S. for treating e.g. diffuse large B cell lymphoma upfront. Andrew73 20:28, 22 October 2005 (UTC)

The same is true in the UK. JFW | T@lk 22:14, 22 October 2005 (UTC)

[edit] SLE

I could not find one nice representative study to illustrate the SLE thing. PMID 15550531 is a hodgepodge of diseases and not really useful. JFW | T@lk 22:30, 3 January 2006 (UTC)

[edit] Epitope on CD20

PMID 16705086 - they've been looking for the bit of CD20 that rituximab binds to. JFW | T@lk 21:12, 6 September 2006 (UTC)

[edit] NHS approval

I'm not knowledgeable enough to be sure where (or if) this news should be mentioned, but it's currently the top story on the BBC News website's Health section. Loganberry (Talk) 00:35, 22 August 2007 (UTC)

NICE TA137 is the NICE technology appraisal for rituximab in follicular lymphoma. JFW | T@lk 08:52, 29 February 2008 (UTC)